首页> 外文期刊>Asian Journal of Pharmaceutical Sciences >Oxidation-strengthened disulfide-bridged prodrug nanoplatforms with cascade facilitated drug release for synergetic photochemotherapy
【24h】

Oxidation-strengthened disulfide-bridged prodrug nanoplatforms with cascade facilitated drug release for synergetic photochemotherapy

机译:氧化加强的二硫纤维桥质纳米纳薄纳薄纳薄型,用于协同光化学疗法的促进药物释放

获取原文
           

摘要

One of the major barriers in utilizing prodrug nanocarriers for cancer therapy is the slow release of parent drug in tumors. Tumor cells generally display the higher oxidative level than normal cells, and also displayed the heterogeneity in terms of redox homeostasis level. We previously found that the disulfide bond-linkage demonstrates surprising oxidation-sensitivity to form the hydrophilic sulfoxide and sulphone groups. Herein, we develop oxidation-strengthened prodrug nanosystem loaded with pyropheophorbide a (PPa) to achieve light-activatable cascade drug release and enhance therapeutic efficacy. The disulfide bond-driven prodrug nanosystems not only respond to the redox-heterogeneity in tumor, but also respond to the exogenous oxidant (singlet oxygen) elicited by photosensitizers. Once the prodrug nanoparticles (NPs) are activated under irradiation, they would undergo an oxidative self-strengthened process, resulting in a facilitated drug cascade release. The IC 50 value of the [email?protected] NPs without irradiation was 2-fold higher than those of NPs plus irradiation. In vivo , the [email?protected] prodrug NPs display prolonged systemic circulation and increased accumulation in tumor site. The [email?protected] NPs showed much higher efficiency than free PTX or the [email?protected] NPs to suppress the growth of 4T1 tumors. Therefore, this novel oxidation-strengthened disulfide-bridged prodrug-nanosystem has a great potential in the enhanced efficacy of cancer synergetic photochemotherapy.
机译:利用前药纳米载体用于癌症治疗的主要障碍之一是肿瘤中母体药物缓慢释放。肿瘤细胞通常显示比正常细胞更高的氧化水平,并且在氧化还原稳态水平方面也显示出异质性。我们以前发现二硫键 - 键合联系表明令人惊讶的氧化敏感性以形成亲水性亚砜和砜基团。在此,我们开发氧化加强的前药纳米系统,其载有纤维黄冰缺剂A(PPA),以实现可光激活的级联药物释放并增强治疗效果。二硫键驱动的前药纳米系统不仅应对肿瘤中的氧化还原异质性,而且还应对光敏剂引发的外源氧化剂(单线氧)。一旦在照射下激活前药纳米颗粒(NPS),它们会经历氧化自增强的方法,导致促进的药物级联释放。 [邮箱的IC 50值没有照射的NPS的NPS比NPS加辐射高2倍。在体内,[电子邮件吗?受保护的]前药NPS显示延长的全身循环和增加肿瘤部位的积累。 [电子邮件吗?受保护的] NPS显示比免费PTX或[电子邮件?保护] NPS更高的效率,以抑制4T1肿瘤的生长。因此,这种新型氧化强化的二硫化物桥接前药物 - 纳米系统具有巨大的患者协同光化学疗法的疗效。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号